Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Dabixta 110
Unimed Unihealth Pharmaceuticals Ltd.
Generic: Dabigatran
Safety Advices
বাংলা
English
UNSAFE
It is unsafe to consume alcohol with Dabixta 110.
CONSULT YOUR DOCTOR
Dabixta 110 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Dabixta 110 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
SAFE
Dabixta 110 does not usually affect your ability to drive.
CAUTION
Dabixta 110 should be used with caution in patients with severe kidney disease. Dose adjustment of Dabixta 110 may be needed. Please consult your doctor.
Use of Dabixta 110 is not recommended in patients with severe kidney disease.
CAUTION
Dabixta 110 should be used with caution in patients with liver disease. Dose adjustment of Dabixta 110 may be needed. Please consult your doctor.
Medicine Overview of Dabixta 110mg Capsule
Introduction
Dabixta 110 is a medicine known as an anticoagulant or blood thinner. It helps prevent and treat blood clots. It is used to reduce the risk of stroke and heart attack. It prevents and treats clot formation in the veins of your legs, lungs, brain and heart. Dabixta 110 is commonly used in patients with irregular heart rhythm (atrial fibrillation) to prevent clot formation. It also reduces the risk of getting clots in people who have undergone knee or hip replacement surgeries. It can be taken with or without food, but it is best to take them at the same...
... Show moreUses of Dabixta 110
- Stroke prevention
- Deep vein thrombosis
- Pulmonary embolism
Side effects of Dabixta 110
Common
- Bleeding
- Nausea
- Stomach pain
- Indigestion
How to use Dabixta 110
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Dabixta 110 may be taken with or without food, but it is better to take it at a fixed time.
How Dabixta 110 works
Dabixta 110 is a novel oral anticoagulant (NOAC). It works by preventing the formation of blood clots in the body.
What if you forget to take Dabixta 110?
If you miss a dose of Dabixta 110, please consult your doctor.
Quick Tips
- Take it as per dose and duration suggested by your doctor.
- Dabixta 110 increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails, using sharp objects or engaging in contact sports (e.g., football and wrestling).
- If you are going to have a surgery or dental treatment, you may be asked to stop taking Dabixta 110 temporarily.
- Your doctor may get a blood test done to check kidney function before starting treatment with this medicine.
- Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
- Do not stop taking the medication without talking to your doctor.
Brief Description
Indication
Prophylaxis of postoperative venous thromboembolism, Atrial fibrillation
Administration
May be taken with or without food. Swallow whole, do not chew/crush.
Adult Dose
Oral Prophylaxis of postoperative venous thromboembolism Adult: Initially, 110 mg given w/in 1-4 hr after surgery followed by 220 mg once daily for a total of 10 days after (knee replacement) or 28-35 after (hip replacement). Reduce dose to 150 mg once daily if given concurrently w/ amiodarone, verapamil or quinidine. Elderly: >75 yr Initially, 75 mg given w/in 1-4 hr after surgery followed by 150 mg once daily for a total of 10 days after (knee replacement) or 28-35 after (hip replacement). Atrial fibrillation Adult: 150 mg bid, reduce dose to 110 mg bid if given concurrently w/ verapamil....
... Show moreRenal Dose
Prophylaxis of postoperative venous thromboembolism
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<30 Contraindicated.
30-50 Initial: 75 mg w/in 1-4 hr after surgery followed by 150 mg once daily for a total of 10 days after (knee replacement) or 28-35 days after (hip replacement). Max: 75 in patients taking w/ verapamil.
Atrial fibrillation
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<30 Contraindicated.
30-50 110 mg bid.
Contraindication
Active pathological bleeding or patient at high risk for bleeding. Patients w/ prosthetic heart valve. Severe renal impairment. Concomitant use w/ antiplatelets, other anticoagulants, thrombolytics, dronedarone, P-glycoprotein inducers (e.g. carbamazepine, rifampicin, phenytoin and St John's wort) and P-glycoprotein strong inhibitors (e.g. ciclosporin, systemic ketoconazole, itraconazole, and tacrolimus).
Mode of Action
Dabigatran is a competitive, selective, reversible direct inhibitor of thrombin. It inhibits thrombin-induced platelet aggregation and the conversion of fibrinogen to fibrin thus preventing thrombus formation.
Precaution
Increased risk of haemorrhage and stroke. Renal and hepatic impairment. Pregnancy, lactation, elderly, childn. Monitoring Parameters Monitor renal function prior to initiation and periodically thereafter.
Side Effect
>10%
Dyspepsia and gastritis (35%; compared with warfarin [24%])
Any bleed (16.6%; compared with warfarin [18.4%])
1-10%
Major bleed (3.3%; compared with warfarin [3.6%])
Life-threatening bleed (1.5%; compared with warfarin [1.9%])
<1%
Intracranial hemorrhage (0.3%; compared with warfarin [0.8%])
Hypersensitivity, including urticaria, rash, pruritus (<0.1%)
Pregnancy Category Note
Risk Summery Limited available data on use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes; there are risks to mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in mother and fetus associated with use of anticoagulants Pregnancy confers an increased risk for thromboembolism that is higher for women with underlying thromboembolic disease and certain high-risk pregnancy conditions; published data describe that women with previous history of venous thrombosis are at high risk for recurrence during pregnancy Use of anticoagulants, may increase risk of bleeding in fetus and neonate; monitor neonates...
... Show moreInteraction
May increase risk of bleeding w/ NSAIDs. Clarithromycin may increase the serum levels of dabigatran.
Potentially Fatal: P-glycoprotein inducers (e.g. carbamazepine, rifampicin, and phenytoin) decreases systemic exposure of dabigatran. P-glycoprotein strong inhibitors (e.g. ciclosporin, systemic ketoconazole, itraconazole, and tacrolimus) and dronedarone increases systemic exposure of dabigatran. Increased bleeding risk w/ antiplatelets, other anticoagulants and thrombolytics.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
